

Charalabos-Markos Dintsios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8841548/publications.pdf>

Version: 2024-02-01

30
papers

600
citations

687363

13
h-index

610901

24
g-index

33
all docs

33
docs citations

33
times ranked

537
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 369-375.	0.5	142
2	Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. <i>European Journal of Health Economics</i> , 2014, 15, 577-589.	2.8	76
3	Using the Analytic Hierarchy Process to Elicit Patient Preferences. <i>Patient</i> , 2012, 5, 225-237.	2.7	52
4	Reflections on the Changing Face of German Pharmaceutical Policy. <i>Pharmacoeconomics</i> , 2011, 29, 549-553.	3.3	39
5	Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases. <i>Value in Health</i> , 2018, 21, 525-531.	0.3	32
6	Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany. <i>Health Policy</i> , 2014, 118, 242-254.	3.0	26
7	Using the Analytic Hierarchy Process to Elicit Patient Preferences. <i>Patient</i> , 2012, 5, 225-237.	2.7	25
8	Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): study protocol for a cluster-randomised controlled trial. <i>Implementation Science</i> , 2015, 10, 82.	6.9	23
9	Implementation of a multicomponent intervention to prevent physical restraints in nursing home residents (IMPRINT): study protocol for a cluster-randomised controlled trial. <i>BMC Geriatrics</i> , 2015, 15, 86.	2.7	18
10	Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. <i>Health Economics Review</i> , 2014, 4, 2.	2.0	17
11	Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negotiations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience. <i>Value in Health</i> , 2016, 19, 1016-1025.	0.3	16
12	Market withdrawals of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. <i>Health Economics Review</i> , 2018, 8, 23.	2.0	15
13	Predictors of negotiated prices for new drugs in Germany. <i>European Journal of Health Economics</i> , 2020, 21, 1049-1057.	2.8	15
14	Questioning Patient Subgroups for Benefit Assessment: Challenging the German Gemeinsamer Bundesausschuss Approach. <i>Value in Health</i> , 2014, 17, 307-309.	0.3	13
15	Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study. <i>Diabetes Care</i> , 2021, 44, 407-415.	8.6	12
16	Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs. <i>Health Policy</i> , 2018, 122, 599-606.	3.0	11
17	Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany. <i>Value in Health</i> , 2018, 21, 698-706.	0.3	9
18	Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified?. <i>Health Economics Review</i> , 2016, 6, 46.	2.0	7

#	ARTICLE	IF	CITATIONS
19	INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 196-204.	0.5	7
20	Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany. <i>European Journal of Health Economics</i> , 2019, 20, 45-57.	2.8	7
21	Determinants of Orphan Drug Prices in Germany. <i>Pharmacoeconomics</i> , 2020, 38, 397-411.	3.3	7
22	Quantified patient preferences for lifestyle intervention programs for diabetes prevention—a protocol for a systematic review. <i>Systematic Reviews</i> , 2018, 7, 214.	5.3	6
23	Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree. <i>Health Economics Review</i> , 2019, 9, 35.	2.0	6
24	How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 287-290.	2.1	3
25	Re: “Early benefit assessment of new drugs in Germany” Results from 2011 to 2012 [Health Policy 116 (2014) 147-153]. <i>Health Policy</i> , 2014, 118, 271.	3.0	2
26	Letter to the editor of the <i>Journal of Affective Disorders</i> : Supporting the guideline's quest for real direct costs of depression care. <i>Journal of Affective Disorders</i> , 2017, 208, 101-102.	4.1	2
27	Re. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 362.	1.6	1
28	Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 145-157.	1.4	1
29	A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, , 1-15.	1.4	0
30	Health Technology Assessment und seine Relevanz für Market Access. , 2020, , 177-199.		0